LSTA

⚡ 1-Minute Take

Data sources: market data, fundamentals, news providers. Data may be delayed.

Key Statistics

📰 Latest News

Lisata Therapeutics pioneers cellular therapies targeting critical unmet needs in vascular and kidney diseases, offering a compelling investment opportunity in regenerative medicine with Phase II clinical trials underway and a SAKIGAKE designation for HONEDRA, potentially unlocking significant value in a growing market.

About LSTA

Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cellular therapies. Their pipeline includes HONEDRA, XOWNA, and CLBS201, targeting critical limb ischemia, coronary microvascular dysfunction, and chronic kidney disease.

Lisata Therapeutics, Inc. Company Overview

Lisata Therapeutics, Inc., established in 1980 and headquartered in Basking Ridge, New Jersey, is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative cellular therapies. Originally incorporated as NeoStem, Inc., the company transitioned to Caladrius Biosciences, Inc. in June 2015 before rebranding as Lisata Therapeutics, Inc. on September 15, 2022. Lisata's core focus lies in reversing disease progression and promoting tissue regeneration through advanced cellular therapeutics. The company's pipeline features three primary product candidates: HONEDRA, a SAKIGAKE-designated therapy in Phase II clinical trials for critical limb ischemia (CLI); XOWNA, currently in Phase IIb clinical trials for coronary microvascular dysfunction (CMVD); and CLBS201, a CD34+ cell therapy targeting pre-dialysis patients with chronic kidney disease (CKD). These therapies represent a targeted approach to address significant unmet medical needs within the cardiovascular and renal therapeutic areas. Lisata's strategic focus on cellular therapies positions it within a rapidly evolving field of regenerative medicine, with the potential to deliver transformative treatments for patients suffering from debilitating conditions.

Investment Thesis

Lisata Therapeutics presents a compelling investment opportunity due to its focused pipeline of cellular therapies targeting significant unmet medical needs. The SAKIGAKE designation for HONEDRA highlights its potential in treating critical limb ischemia, while XOWNA addresses coronary microvascular dysfunction, and CLBS201 targets chronic kidney disease. With a market capitalization of $0.04 billion, Lisata offers significant upside potential if clinical trials are successful. The company's gross margin of 100.0% suggests a strong pricing power for its therapies upon commercialization. Key value drivers include positive Phase II clinical trial results for HONEDRA and XOWNA, potential partnerships for late-stage development and commercialization, and expansion of the pipeline through strategic acquisitions or in-licensing agreements. This makes LSTA an attractive investment within the biotechnology sector.

Key Financial Highlights

• Market capitalization of $0.04 billion, indicating potential for growth if clinical trials are successful.
• Gross margin of 100.0%, reflecting strong potential pricing power for its therapies upon commercialization.
• HONEDRA received SAKIGAKE designation, highlighting its potential in treating critical limb ischemia.
• Phase II clinical trials underway for HONEDRA (critical limb ischemia) and XOWNA (coronary microvascular dysfunction), representing key milestones.
• Beta of 1.27, suggesting higher volatility compared to the overall market.

Industry Context

Lisata Therapeutics operates within the biotechnology industry, a sector characterized by high innovation and significant growth potential. The market for cellular therapies is expanding rapidly, driven by advancements in regenerative medicine and the increasing prevalence of chronic diseases. Lisata's focus on vascular and kidney diseases positions it within specific niches of this broader market. Competitors include companies like CASI Pharmaceuticals, Inc. (CASI), Celgene Corporation (CLGN), Clearside Biomedical, Inc. (CLSD), Enlivex Therapeutics Ltd. (ENLV), and KalVista Pharmaceuticals, Inc. (KLTO). The industry is characterized by intense competition, high regulatory hurdles, and significant R&D investment.

Growth Opportunities

• Expansion of HONEDRA's clinical applications: Leveraging the SAKIGAKE designation, Lisata can explore additional indications for HONEDRA beyond critical limb ischemia. The market for peripheral artery disease (PAD), which includes CLI, is estimated to reach billions of dollars, providing a significant growth opportunity. Timeline: Ongoing clinical trials with potential for expansion within the next 2-3 years.
• Advancement of XOWNA for coronary microvascular dysfunction: Successful completion of Phase IIb trials for XOWNA could unlock a substantial market in coronary microvascular dysfunction (CMVD). The prevalence of CMVD is high, particularly among women, creating a significant unmet medical need. Timeline: Phase IIb trial results expected within the next 1-2 years, with potential for Phase III initiation thereafter.
• Development and commercialization of CLBS201 for chronic kidney disease: CLBS201 represents a potential breakthrough in treating chronic kidney disease (CKD) in pre-dialysis patients. The global CKD market is substantial and growing, driven by the aging population and increasing prevalence of diabetes and hypertension. Timeline: Continued development and potential partnerships for commercialization within the next 3-5 years.
• Strategic partnerships and collaborations: Lisata can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline assets. These partnerships can provide access to funding, expertise, and established distribution networks. Timeline: Ongoing efforts with potential for partnerships within the next 1-2 years.
• Pipeline expansion through acquisitions or in-licensing: Lisata can expand its pipeline by acquiring or in-licensing promising new cellular therapies or related technologies. This would diversify its portfolio and reduce reliance on its current lead candidates. Timeline: Ongoing evaluation of potential acquisition or in-licensing opportunities.

Competitive Advantages

• Proprietary cellular therapy technologies.
• SAKIGAKE designation for HONEDRA, providing regulatory advantages.
• Clinical trial data demonstrating efficacy and safety.
• Strong intellectual property portfolio.
• Expertise in cellular therapy development and manufacturing.

Strengths

• Proprietary cellular therapy platform.
• SAKIGAKE designation for HONEDRA.
• Targeted approach to unmet medical needs.
• Experienced management team.

Weaknesses

• Clinical-stage company with no approved products.
• Reliance on successful clinical trial outcomes.
• Limited financial resources.
• High cash burn rate.

Opportunities

• Positive clinical trial results driving valuation.
• Strategic partnerships for development and commercialization.
• Expansion into new therapeutic areas.
• Acquisition of complementary technologies.

Threats

• Clinical trial failures.
• Regulatory hurdles and delays.
• Competition from established pharmaceutical companies.
• Difficulty in securing funding.

What LSTA Does

• Develop cellular therapies for reversing disease.
• Promote regeneration of damaged tissue.
• Focus on critical limb ischemia (CLI) treatment with HONEDRA.
• Develop XOWNA for coronary microvascular dysfunction (CMVD).
• Create CLBS201, a CD34+ cell therapy for chronic kidney disease (CKD).
• Conduct Phase II clinical trials for HONEDRA and XOWNA.
• Target pre-dialysis patients with CLBS201.

Business Model

• Develop and patent novel cellular therapies.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approvals for commercialization.
• Potentially partner with larger pharmaceutical companies for distribution.
• Generate revenue through sales of approved therapies.

Key Customers

• Patients with critical limb ischemia (CLI).
• Patients with coronary microvascular dysfunction (CMVD).
• Pre-dialysis patients with chronic kidney disease (CKD).
• Healthcare providers and hospitals.
• Potential pharmaceutical partners.

Competitors

• CASI Pharmaceuticals, Inc. (CASI): Focuses on developing and commercializing innovative therapeutics and pharmaceutical products in China.
• Celgene Corporation (CLGN): Develops therapies for cancer and inflammatory disorders (acquired by Bristol Myers Squibb).
• Clearside Biomedical, Inc. (CLSD): Develops therapies for retinal diseases.
• Enlivex Therapeutics Ltd. (ENLV): Develops immunotherapy treatments for organ dysfunction and immune system imbalances.
• KalVista Pharmaceuticals, Inc. (KLTO): Develops oral therapies for hereditary angioedema and other plasma kallikrein-mediated diseases.

Catalysts

• Upcoming: Phase II clinical trial results for HONEDRA in critical limb ischemia.
• Upcoming: Phase IIb clinical trial results for XOWNA in coronary microvascular dysfunction.
• Ongoing: Potential for strategic partnerships to fund development and commercialization.
• Ongoing: Expansion of pipeline through acquisitions or in-licensing.

Risks

• Potential: Clinical trial failures for HONEDRA, XOWNA, or CLBS201.
• Potential: Regulatory delays or non-approval of therapies.
• Ongoing: Competition from larger pharmaceutical companies with greater resources.
• Ongoing: Difficulty in securing additional funding to support operations.
• Ongoing: Dependence on a limited number of product candidates.

FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Related Stocks in Healthcare/Biotechnology

Browse More

Next Steps